Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis or Non-radiographic Axial Spondyloarthritis

NCT03926195 is registered in ClinicalTrials.gov with Lakefront Biotherapeutics NV as lead sponsor.

NCT NCT03926195
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03926195 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis or Non-radiographic Axial Spondyloarthritis
Lead sponsor
Lakefront Biotherapeutics NV
Phase
Phase 2
Overall status
Completed
Start date
May 28, 2019
Completion date
May 10, 2023
Enrollment
109 (actual)
Sites
71

Conditions

As the registry lists them; a condition with its own page is linked.

ankylosing spondylitis, non-radiographical axial spondyloarthritis, psoriatic arthritis, rheumatoid arthritis